Cargando…

SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey

BACKGROUND: The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May–June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34–1·13). We aimed to assess the more recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Murhekar, Manoj V, Bhatnagar, Tarun, Selvaraju, Sriram, Saravanakumar, V, Thangaraj, Jeromie Wesley Vivian, Shah, Naman, Kumar, Muthusamy Santhosh, Rade, Kiran, Sabarinathan, R, Asthana, Smita, Balachandar, Rakesh, Bangar, Sampada Dipak, Bansal, Avi Kumar, Bhat, Jyothi, Chopra, Vishal, Das, Dasarathi, Deb, Alok Kumar, Devi, Kangjam Rekha, Dwivedi, Gaurav Raj, Khan, S Muhammad Salim, Kumar, C P Girish, Kumar, M Sunil, Laxmaiah, Avula, Madhukar, Major, Mahapatra, Amarendra, Mohanty, Suman Sundar, Rangaraju, Chethana, Turuk, Alka, Baradwaj, Dinesh Kumar, Chahal, Ashrafjit S, Debnath, Falguni, Haq, Inaamul, Kalliath, Arshad, Kanungo, Srikanta, Kshatri, Jaya Singh, Lakshmi, G G J Naga, Mitra, Anindya, Nirmala, A R, Prasad, Ganta Venkata, Qurieshi, Mariya Amin, Sahay, Seema, Sangwan, Ramesh Kumar, Sekar, Krithikaa, Shukla, Vijay Kumar, Singh, Prashant Kumar, Singh, Pushpendra, Singh, Rajeev, Varma, Dantuluri Sheethal, Viramgami, Ankit, Panda, Samiran, Reddy, D C S, Bhargava, Balram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906675/
https://www.ncbi.nlm.nih.gov/pubmed/33515512
http://dx.doi.org/10.1016/S2214-109X(20)30544-1
_version_ 1783655340683821056
author Murhekar, Manoj V
Bhatnagar, Tarun
Selvaraju, Sriram
Saravanakumar, V
Thangaraj, Jeromie Wesley Vivian
Shah, Naman
Kumar, Muthusamy Santhosh
Rade, Kiran
Sabarinathan, R
Asthana, Smita
Balachandar, Rakesh
Bangar, Sampada Dipak
Bansal, Avi Kumar
Bhat, Jyothi
Chopra, Vishal
Das, Dasarathi
Deb, Alok Kumar
Devi, Kangjam Rekha
Dwivedi, Gaurav Raj
Khan, S Muhammad Salim
Kumar, C P Girish
Kumar, M Sunil
Laxmaiah, Avula
Madhukar, Major
Mahapatra, Amarendra
Mohanty, Suman Sundar
Rangaraju, Chethana
Turuk, Alka
Baradwaj, Dinesh Kumar
Chahal, Ashrafjit S
Debnath, Falguni
Haq, Inaamul
Kalliath, Arshad
Kanungo, Srikanta
Kshatri, Jaya Singh
Lakshmi, G G J Naga
Mitra, Anindya
Nirmala, A R
Prasad, Ganta Venkata
Qurieshi, Mariya Amin
Sahay, Seema
Sangwan, Ramesh Kumar
Sekar, Krithikaa
Shukla, Vijay Kumar
Singh, Prashant Kumar
Singh, Pushpendra
Singh, Rajeev
Varma, Dantuluri Sheethal
Viramgami, Ankit
Panda, Samiran
Reddy, D C S
Bhargava, Balram
author_facet Murhekar, Manoj V
Bhatnagar, Tarun
Selvaraju, Sriram
Saravanakumar, V
Thangaraj, Jeromie Wesley Vivian
Shah, Naman
Kumar, Muthusamy Santhosh
Rade, Kiran
Sabarinathan, R
Asthana, Smita
Balachandar, Rakesh
Bangar, Sampada Dipak
Bansal, Avi Kumar
Bhat, Jyothi
Chopra, Vishal
Das, Dasarathi
Deb, Alok Kumar
Devi, Kangjam Rekha
Dwivedi, Gaurav Raj
Khan, S Muhammad Salim
Kumar, C P Girish
Kumar, M Sunil
Laxmaiah, Avula
Madhukar, Major
Mahapatra, Amarendra
Mohanty, Suman Sundar
Rangaraju, Chethana
Turuk, Alka
Baradwaj, Dinesh Kumar
Chahal, Ashrafjit S
Debnath, Falguni
Haq, Inaamul
Kalliath, Arshad
Kanungo, Srikanta
Kshatri, Jaya Singh
Lakshmi, G G J Naga
Mitra, Anindya
Nirmala, A R
Prasad, Ganta Venkata
Qurieshi, Mariya Amin
Sahay, Seema
Sangwan, Ramesh Kumar
Sekar, Krithikaa
Shukla, Vijay Kumar
Singh, Prashant Kumar
Singh, Pushpendra
Singh, Rajeev
Varma, Dantuluri Sheethal
Viramgami, Ankit
Panda, Samiran
Reddy, D C S
Bhargava, Balram
author_sort Murhekar, Manoj V
collection PubMed
description BACKGROUND: The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May–June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34–1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India. METHODS: We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3–5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys. FINDINGS: Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8–7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2–8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26–32 infections for every reported COVID-19 case. INTERPRETATION: Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country. FUNDING: Indian Council of Medical Research.
format Online
Article
Text
id pubmed-7906675
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-79066752021-02-26 SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey Murhekar, Manoj V Bhatnagar, Tarun Selvaraju, Sriram Saravanakumar, V Thangaraj, Jeromie Wesley Vivian Shah, Naman Kumar, Muthusamy Santhosh Rade, Kiran Sabarinathan, R Asthana, Smita Balachandar, Rakesh Bangar, Sampada Dipak Bansal, Avi Kumar Bhat, Jyothi Chopra, Vishal Das, Dasarathi Deb, Alok Kumar Devi, Kangjam Rekha Dwivedi, Gaurav Raj Khan, S Muhammad Salim Kumar, C P Girish Kumar, M Sunil Laxmaiah, Avula Madhukar, Major Mahapatra, Amarendra Mohanty, Suman Sundar Rangaraju, Chethana Turuk, Alka Baradwaj, Dinesh Kumar Chahal, Ashrafjit S Debnath, Falguni Haq, Inaamul Kalliath, Arshad Kanungo, Srikanta Kshatri, Jaya Singh Lakshmi, G G J Naga Mitra, Anindya Nirmala, A R Prasad, Ganta Venkata Qurieshi, Mariya Amin Sahay, Seema Sangwan, Ramesh Kumar Sekar, Krithikaa Shukla, Vijay Kumar Singh, Prashant Kumar Singh, Pushpendra Singh, Rajeev Varma, Dantuluri Sheethal Viramgami, Ankit Panda, Samiran Reddy, D C S Bhargava, Balram Lancet Glob Health Articles BACKGROUND: The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May–June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34–1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India. METHODS: We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3–5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys. FINDINGS: Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8–7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2–8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26–32 infections for every reported COVID-19 case. INTERPRETATION: Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country. FUNDING: Indian Council of Medical Research. The Author(s). Published by Elsevier Ltd. 2021-03 2021-01-27 /pmc/articles/PMC7906675/ /pubmed/33515512 http://dx.doi.org/10.1016/S2214-109X(20)30544-1 Text en © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Articles
Murhekar, Manoj V
Bhatnagar, Tarun
Selvaraju, Sriram
Saravanakumar, V
Thangaraj, Jeromie Wesley Vivian
Shah, Naman
Kumar, Muthusamy Santhosh
Rade, Kiran
Sabarinathan, R
Asthana, Smita
Balachandar, Rakesh
Bangar, Sampada Dipak
Bansal, Avi Kumar
Bhat, Jyothi
Chopra, Vishal
Das, Dasarathi
Deb, Alok Kumar
Devi, Kangjam Rekha
Dwivedi, Gaurav Raj
Khan, S Muhammad Salim
Kumar, C P Girish
Kumar, M Sunil
Laxmaiah, Avula
Madhukar, Major
Mahapatra, Amarendra
Mohanty, Suman Sundar
Rangaraju, Chethana
Turuk, Alka
Baradwaj, Dinesh Kumar
Chahal, Ashrafjit S
Debnath, Falguni
Haq, Inaamul
Kalliath, Arshad
Kanungo, Srikanta
Kshatri, Jaya Singh
Lakshmi, G G J Naga
Mitra, Anindya
Nirmala, A R
Prasad, Ganta Venkata
Qurieshi, Mariya Amin
Sahay, Seema
Sangwan, Ramesh Kumar
Sekar, Krithikaa
Shukla, Vijay Kumar
Singh, Prashant Kumar
Singh, Pushpendra
Singh, Rajeev
Varma, Dantuluri Sheethal
Viramgami, Ankit
Panda, Samiran
Reddy, D C S
Bhargava, Balram
SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
title SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
title_full SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
title_fullStr SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
title_full_unstemmed SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
title_short SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
title_sort sars-cov-2 antibody seroprevalence in india, august–september, 2020: findings from the second nationwide household serosurvey
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906675/
https://www.ncbi.nlm.nih.gov/pubmed/33515512
http://dx.doi.org/10.1016/S2214-109X(20)30544-1
work_keys_str_mv AT murhekarmanojv sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT bhatnagartarun sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT selvarajusriram sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT saravanakumarv sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT thangarajjeromiewesleyvivian sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT shahnaman sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT kumarmuthusamysanthosh sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT radekiran sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT sabarinathanr sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT asthanasmita sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT balachandarrakesh sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT bangarsampadadipak sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT bansalavikumar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT bhatjyothi sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT chopravishal sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT dasdasarathi sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT debalokkumar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT devikangjamrekha sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT dwivedigauravraj sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT khansmuhammadsalim sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT kumarcpgirish sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT kumarmsunil sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT laxmaiahavula sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT madhukarmajor sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT mahapatraamarendra sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT mohantysumansundar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT rangarajuchethana sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT turukalka sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT baradwajdineshkumar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT chahalashrafjits sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT debnathfalguni sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT haqinaamul sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT kalliatharshad sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT kanungosrikanta sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT kshatrijayasingh sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT lakshmiggjnaga sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT mitraanindya sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT nirmalaar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT prasadgantavenkata sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT qurieshimariyaamin sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT sahayseema sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT sangwanrameshkumar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT sekarkrithikaa sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT shuklavijaykumar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT singhprashantkumar sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT singhpushpendra sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT singhrajeev sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT varmadantulurisheethal sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT viramgamiankit sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT pandasamiran sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT reddydcs sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT bhargavabalram sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey
AT sarscov2antibodyseroprevalenceinindiaaugustseptember2020findingsfromthesecondnationwidehouseholdserosurvey